Pharma BD Deal Intelligence
ANI Pharmaceuticals announced a recommended public offer to acquire Sweden's Egetis Therapeutics AB for SEK 11.25 per share in cash, a 27% premium to the 60-day volume-weighted average price, together with Egetis' outstanding convertible debt and warrants. Including outstanding incentive programs the offer values Egetis at approximately SEK 5.6 billion (about $560 million), financed through cash on hand and new debt financing provided by JPMorgan Chase Bank, N.A. The transaction would add Emcitate (tiratricol), approved by the European Commission in February 2025 and by the US FDA in September 2026 as the first and only treatment for peripheral thyrotoxicosis in adult and pediatric patients with MCT8 deficiency. Shareholders representing approximately 42.2% of outstanding shares have undertaken to accept the offer. The acceptance period was expected to run from on or around November 20, 2026 to on or around December 18, 2026, subject to a 90% minimum acceptance condition and regulatory approvals.
← Browse all deals · How we score deals
More: 2026 deals